On the applicability of [

In recent years extra-corporal application of boron neutron capture therapy (BNCT) was evaluated for liver primary tumors or liver metastases. A prerequisite for such a high-risk procedure is proof of preferential delivery and high uptake of aTumor bearing mice (hepatocellular carcinoma cell line, HuH-7) were either subject of a [We found a significant correlation between [[Despite differences in chemical structure and administered dose [